This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

SinoMab BioScience Limited


We are the first Hong Kong-based listed biopharmaceutical company (Stock Code: 03681.HK) dedicated to the research, development, manufacturing and commercialisation of innovative therapeutics for the treatment of immunological diseases and neurological diseases. Headquartered in Hong Kong, we strive to become a leading global biopharmaceutical company for the development of novel drugs to fulfil unmet medical needs through our Hong Kong based innovative R&D, and PRC-based manufacturing capabilities. We have been dedicated to R&D since our inception, and have built a pipeline of mAb-based biologics and new chemical entities addressing indications against a plethora of immunological diseases.
Our flagship product Suciraslimab(SM03) is a potential global first-in-class anti-CD22 antibody for the treatment of rheumatoid arthritis (RA). Phase 3 clinical study results demonstrated its compelling therapeutic effect and safety profile. BLA for Suciraslimab in the treatment of RA was accepted by the NMPA for review in Sep 2023. An IND for neurological diseases, MCI or mild dementia, has also been accepted by the NMPA for review in Nov 2023.
Our another core pipeline, SM17, is a potential first-in-class and first-in-target antibody for treating autoimmune and allergic inflammatory diseases via the attenuation of IL-25 signaling. Pre-clinical results indicated it is efficacious in treating atopic dermatitis and asthma. Phase 1 study in the US completed demonstrated good safety profile over existing products.